Medtronic account plan
Healthcare technology innovation
At a glance
Medtronic is an Ireland-incorporated medical device maker selling in 150+ countries: $36,364 million FY2026 net sales and over 95,000 employees.
Medtronic plc, founded in 1949, incorporated in Ireland and run operationally from the Minneapolis, Minnesota area, develops and sells device-based medical therapies to hospitals, ambulatory surgical centers, physician offices and alternate care sites in more than 150 countries, through direct sales representatives and distributors. In fiscal 2026 (ended April 24, 2026) net sales were $36,364 million (+8%), split almost evenly between the U.S. ($18,103 million) and international markets ($18,261 million), with GAAP net income attributable to Medtronic of $4,801 million and free cash flow of $5,426 million. It has over 95,000 full-time employees, 43% of them in the U.S. or Puerto Rico. Geoffrey S. Martha is Chairman and CEO; the diabetes business, MiniMed Group, listed on Nasdaq in March 2026 and remains about 90% owned pending full separation.
Business units
Cardiovascular Portfolio
$13,976 million FY2026 net sales, about 38% of net salesPacemakers (Micra), defibrillators (Aurora EV-ICD), pulsed field ablation (PulseSelect, Affera Sphere-9 and Sphere-360), Evolut TAVR valves, aortic stent grafts, coronary stents and the Symplicity Spyral renal denervation system. It grew 12% in FY2026 and 20% in Q1 FY2027, when it was reorganised into four divisions. Led by Skip Kiil, EVP and President.
Neuroscience Portfolio
$10,287 million FY2026 net sales, about 28% of net salesCranial and spinal technologies (the AiBLE ecosystem, Stealth AXiS, Mazor robotics, spinal implants), neurovascular, ENT and pelvic health products (Pipeline, Solitaire, InterStim, Altaviva) and neuromodulation (Inceptiv, Percept DBS). It grew 4% in FY2026 and 10% in Q1 FY2027. Led by Dr. Kweli Thompson, EVP and President since June 2026.
Medical Surgical Portfolio
$8,815 million FY2026 net sales, about 24% of net salesSurgical stapling, LigaSure vessel sealing, Valleylab energy, the Hugo robotic-assisted surgery system, hernia mesh, sutures and endoscopy, plus acute care and monitoring (Nellcor, McGRATH MAC, Microstream). It grew 5% in FY2026, with advanced stapling hit by bariatric volumes. Led by Michael Marinaro.
Diabetes (MiniMed Group)
$3,112 million FY2026 net sales, about 9% of net salesInsulin pumps, CGM systems and consumables, driven by the MiniMed 780G system. MiniMed listed on Nasdaq on March 9, 2026, Medtronic holds about 90.03%, and the separation is planned to complete within fiscal 2027.
Strategic priorities
- Innovation-driven growth platforms
- Growth is led by Cardiac Ablation Solutions (past $2 billion of trailing twelve-month revenue), Symplicity renal denervation, Hugo robotics, Altaviva and Stealth AXiS, alongside the foundational CRM, spine and surgical businesses.
- Data, AI and automation
- One of three strategic areas in the FY2026 10-K is to "Turn data, AI, and automation into action", tailoring therapies in real time and supporting remote monitoring and care delivery.
- Margin expansion and cost-out
- The CFO's priorities are "Portfolio simplification, SKU rationalization, cost-out and broader supply-chain initiatives"; more than 9,000 SKUs were rationalized and FY27 operating profit is expected to grow about 10%.
- Complete the MiniMed separation
- Medtronic intends to close the Diabetes separation before fiscal year-end to "create two focused companies"; related restructuring is expected to cost $300 million to $500 million pre-tax through fiscal year 2029.
- Tuck-in M&A and venture investments
- Recent acquisitions (CathWorks, Scientia Vascular, SPR Therapeutics) should add over $150 million of inorganic growth in FY27, and 16 venture investments were made in FY26.
Latest results
In Q1 fiscal 2027 (three months ended July 31, 2026), net sales rose 14% to $9,756 million from $8,578 million, with organic growth of 13.7%; an extra selling week added about $570 million. Cardiovascular grew 20% to $3,927 million, led by Electrophysiology Therapies (+30%), Neuroscience 10% and Medical Surgical 10%. Non-GAAP EPS was $1.45 against $1.26, and free cash flow was $1,290 million against $584 million. Management raised FY27 guidance to organic growth of 7.25% to 7.75% and EPS of $5.94 to $6.00, and guided Q2 to roughly 6% organic growth.
Investments and deals
- CathWorks
- Acquired April 20, 2026 for $525 million of consideration, including $115 million contingent, adding FFRangio to coronary.
- Scientia Vascular
- Closed June 12, 2026 for $681 million of total consideration, including $123 million contingent, adding neurovascular access products to Specialty Therapies.
- SPR Therapeutics
- Closed July 16, 2026 for $654 million, adding temporary peripheral nerve stimulation to Neuromodulation.
- Robotics partnerships
- A strategic investment and distribution agreement for Cornerstone Robotics' Sentire Surgical System in select markets outside the U.S., alongside Hugo, which should pass 50,000 completed procedures by year-end.
- Capex and buybacks
- FY2026 capex was $1,904 million; 10 million shares were repurchased at an average of $93.25 in FY2026, and the quarterly dividend rose to $0.72.
Challenges and risks
- Tariffs and trade policy
- Medtronic estimates a tariff cost of about $250 million in FY27; IEEPA tariff refunds are being processed after the Supreme Court ruling of February 20, 2026.
- Pricing pressure and China tenders
- Price-sensitive hospitals, GPOs and volume-based procurement tenders in China weigh on pricing.
- Bariatric volumes and GLP-1 drugs
- Advanced stapling declined on shifts to robotic surgery and lower bariatric volumes, and the 10-K names GLP-1 drug makers as competitors; the Medical Surgical unit's fair value exceeded carrying value by only about 12%.
- Regulatory, quality and supply
- Risks include FDA and EU MDR approvals, recalls such as Pipeline Vantage, sole-source components and constrained sterilization capacity.
- Separation execution
- The MiniMed separation carries execution risk, with a Transition Services Agreement of up to 24 months.
What leadership says
“We are executing, and this quarter's results are a clear proof point.”
“laser-focused on translating stronger growth and enhanced efficiency into durable earnings leverage”
“MedTech is structurally resilient because the fundamentals are durable”
Where a supplier can help
- Supply-chain and SKU simplification
- Tied to the margin expansion and cost-out priority: supply-chain, procurement and portfolio-analytics suppliers supporting SKU rationalization and cost-down.
- Data and AI in care delivery
- Tied to the data, AI and automation priority: software, data and remote-monitoring partners for real-time therapy tailoring.
- Separation and integration services
- Tied to the MiniMed separation and the CathWorks, Scientia and SPR acquisitions: IT carve-out, transition services and integration support.
- Commercial scale-up of growth platforms
- Tied to Cardiac Ablation, Symplicity and Altaviva growth: physician training, referral and market-access tools as installed bases and procedure volumes expand.
- Tariff and trade compliance
- Tied to the tariff challenge: customs, sourcing and trade-compliance services as Medtronic manages about $250 million of FY27 tariff cost.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Medtronic?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Form 10-K for the fiscal year ended April 24, 2026
- Medtronic plc describes itself as "the leading global healthcare technology company": incorporated in Ireland (principal executive office in Ireland, main operational offices in the Minneapolis area), serving healthcare systems, physicians and patients in more than 150 countries, with over 95,000 full-time employees (43% in the U.S. or Puerto Rico).
- FY2026 (year ended April 24, 2026): net sales $36,364 million, up 8% from $33,537 million; U.S. $18,103 million (+5%), international $18,261 million (+12%). GAAP diluted EPS $3.73, non-GAAP diluted EPS $5.53; operating cash flow $7,330 million, free cash flow $5,426 million.
- Three reportable segments: Cardiovascular ($13,976 million, +12%), Neuroscience ($10,287 million, +4%) and Medical Surgical ($8,815 million, +5%); Diabetes ($3,112 million, +13%) is no longer a reportable segment after the MiniMed IPO.
- Fastest grower: Cardiac Rhythm & Heart Failure, +17% to $7,504 million, driven by pulsed field ablation (PulseSelect, Affera Sphere-9, Sphere-360), Micra leadless pacemakers and the Aurora EV-ICD.
- Portfolio reshaping: MiniMed Group (Diabetes) IPO on March 9, 2026 (net proceeds $538 million; Medtronic keeps about 90.03%), with full separation planned within the next fiscal year; acquisitions of CathWorks ($525 million, April 2026), Scientia Vascular (closed June 2026) and SPR Therapeutics (about $650 million, announced May 2026).
- Strategy: accelerate innovation-driven growth, deliver better outcomes and experiences for patients and providers, and "Turn data, AI, and automation into action"; growth platforms include Hugo robotic surgery, the AiBLE spine ecosystem and Stealth AXiS, Symplicity renal denervation and Altaviva.
- Costs and risks: estimated pre-tax net tariff impact of $250 million in FY2027; restructuring tied to the MiniMed separation expected to cost $300 million to $500 million; pricing pressure (incl. China volume-based procurement), GLP-1 drugs weighing on bariatric procedures, and the long-running U.S. tax litigation over Puerto Rico income allocation.
- Capital: total debt $28.0 billion; dividends of $0.71 per quarter in FY2026, raised to $0.72 for Q1 FY2027; $1.2 billion left on the $5.0 billion buyback authorization.
- Form 10-Q for the quarter ended July 31, 2026 (Q1 fiscal 2027)
- Q1 FY2027 (three months ended July 31, 2026, including an extra week because fiscal 2027 has 53 weeks): net sales $9,756 million, +14% from $8,578 million. The extra week added an estimated $570 million.
- By segment: Cardiovascular $3,927 million (+20%), Neuroscience $2,678 million (+10%), Medical Surgical $2,279 million (+10%), Diabetes $843 million (+17%). U.S. sales were $4,906 million (+16%), international $4,850 million (+11%).
- New Cardiovascular structure from Q1: Electrophysiology Therapies ($2,218 million, +30%, driven by pulsed field ablation and CRM), Interventional Cardiology Therapies ($894 million, +7%), CardioVascular Surgery ($477 million, +9%), Peripheral Vascular Health ($338 million, +12%).
- GAAP diluted EPS $1.14 (from $0.81); non-GAAP diluted EPS $1.45 (from $1.26). Free cash flow $1,290 million (from $584 million).
- Acquisitions closed: Scientia Vascular ($681 million of total consideration, June 12, 2026) and SPR Therapeutics ($654 million, July 16, 2026). The MiniMed separation is planned within this fiscal year.
- Total debt was $28.2 billion and $450 million of commercial paper was outstanding; 3 million shares were repurchased at $81.56, with about $1.0 billion of the authorization left.
- Tariffs had no material year-over-year impact on cost of sales once refunds following the February 2026 Supreme Court IEEPA ruling are counted. Medical Surgical goodwill ($19.7 billion) had only about 12% headroom at the last impairment test.
- Q1 FY27 earnings call commentary (prepared remarks)
- Q1 FY2027 prepared remarks (September 1, 2026) by Chairman and CEO Geoff Martha and CFO Thierry Piéton: revenue of $9.8B and adjusted EPS of $1.45, organic growth 13.7%. The extra selling week added about $570M, or 670 basis points.
- Cardiac Ablation Solutions grew 88% worldwide (139% in the U.S.) and passed $2 billion of trailing twelve-month revenue. Sphere-9 gained 9 points of U.S. share and the U.S. Affera installed base grew more than 35% sequentially.
- Cardiac Rhythm Management (more than $5.5 billion in annual revenue) grew 15%, Cranial & Spinal Technologies 13%, and Surgical (over $6 billion) 9%; Pelvic Health grew 15% as Altaviva procedures doubled sequentially.
- Robotics: Hugo is expected to pass 50,000 completed procedures by fiscal year-end. A strategic investment and distribution agreement for Cornerstone Robotics' Sentire system covers select markets outside the U.S., and Touch Surgery is used in more than 1,500 operating rooms.
- Margins: adjusted gross margin 65.2%, adjusted operating margin 23.7%. More than 9,000 SKUs were rationalized in the quarter.
- Guidance raised: FY2027 organic revenue growth of 7.25% to 7.75% and EPS of $5.94 to $6.00. Q2 is expected at roughly 6% organic growth and EPS of $1.32 to $1.34.
- The MiniMed separation is intended to close before fiscal year-end. Investor Day is scheduled for December 10th and 11th.
- Q4 FY26 earnings call commentary (prepared remarks)
- Q4 FY2026 prepared remarks (June 3, 2026) by Geoff Martha (Chairman and CEO) and Thierry Piéton (CFO): Q4 revenue $9.8 billion, +9.9% reported and +6.6% organic. FY2026 revenue $36.4 billion, +5.8% organic, the "strongest top-line performance in 10 years". Adjusted EPS $1.55 for Q4 and $5.53 for the year.
- Cardiac Ablation Solutions grew 78% (124% in the U.S.) and gained 8 points of U.S. share; PFA grew 145%. CAS is annualizing over $2 billion in a $14 billion market that grew about 20% in Q4.
- Symplicity is annualizing at $100 million and average weekly procedures have doubled since the NCD. Hugo procedure growth is 2-3x the market, with 510(k) submissions for general surgery and gynecology.
- Portfolio and M&A: MiniMed IPO completed; CathWorks closed; Scientia, SPR Therapeutics, Beluga Medical and CardioACC announced. Nearly $2.0 billion of investments were closed or announced in Q4, plus 16 venture investments in the year (about $250 million).
- Free cash flow was $5.4 billion in FY26, and the year ended with $9.2 billion in cash and investments.
- Initial FY27 guidance: organic growth of 6.75% to 7.25% and EPS of $5.90 to $6.00, including about $250M of tariffs, 2% dilution from M&A and a full year of Diabetes.
- Leadership: Brett Wall leaves; Dr. Kweli Thompson becomes EVP and President of Neuroscience.
Questions about Medtronic
What does Medtronic do?
Medtronic develops, manufactures and sells device-based medical therapies, from pacemakers and ablation systems to spine robotics and surgical staplers, to healthcare providers in more than 150 countries.
What is Medtronic's revenue?
Net sales were $36,364 million in fiscal 2026 (ended April 24, 2026), up 8%. In Q1 fiscal 2027 net sales were $9,756 million.
How many employees does Medtronic have?
Medtronic has over 95,000 full-time employees, 43% of them in the U.S. or Puerto Rico.
Who leads Medtronic?
Geoffrey S. Martha is Chairman and CEO, and Thierry Piéton is EVP and CFO.
What is Medtronic's strategy?
Accelerating innovation-driven growth through platforms such as pulsed field ablation, renal denervation and robotics, turning data and AI into action, cutting costs and separating its diabetes business.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)